Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Price, Quote, News and Overview

NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD

1.83  +0.01 (+0.55%)

SKYE Quote, Performance and Key Statistics

SKYE BIOSCIENCE INC

NASDAQ:SKYE (4/28/2025, 12:33:41 PM)

1.83

+0.01 (+0.55%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.51
52 Week Low1.14
Market Cap56.68M
Shares30.97M
Float30.58M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08/amc
IPO02-24 2014-02-24


SKYE short term performance overview.The bars show the price performance of SKYE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60

SKYE long term performance overview.The bars show the price performance of SKYE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SKYE is 1.83 USD. In the past month the price decreased by -14.15%. In the past year, price decreased by -86%.

SKYE BIOSCIENCE INC / SKYE Daily stock chart

SKYE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.57 337.33B
AMGN AMGEN INC 14.25 151.80B
GILD GILEAD SCIENCES INC 13.55 130.73B
VRTX VERTEX PHARMACEUTICALS INC 1701.93 126.88B
REGN REGENERON PHARMACEUTICALS 13.28 66.27B
ARGX ARGENX SE - ADR 323.59 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.05B
ONC BEIGENE LTD-ADR N/A 26.93B
BNTX BIONTECH SE-ADR N/A 25.08B
NTRA NATERA INC N/A 20.40B
SMMT SUMMIT THERAPEUTICS INC N/A 18.12B
BIIB BIOGEN INC 7.2 17.36B

About SKYE

Company Profile

SKYE logo image Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Company Info

SKYE BIOSCIENCE INC

11250 El Camino Real, Suite 100

San Diego CALIFORNIA US

Employees: 11

Company Website: https://skyebioscience.com/

Investor Relations: http://ir.skyebioscience.com

Phone: 18584100266

SKYE BIOSCIENCE INC / SKYE FAQ

What is the stock price of SKYE BIOSCIENCE INC today?

The current stock price of SKYE is 1.83 USD. The price increased by 0.55% in the last trading session.


What is the ticker symbol for SKYE BIOSCIENCE INC stock?

The exchange symbol of SKYE BIOSCIENCE INC is SKYE and it is listed on the Nasdaq exchange.


On which exchange is SKYE stock listed?

SKYE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SKYE BIOSCIENCE INC stock?

13 analysts have analysed SKYE and the average price target is 17.68 USD. This implies a price increase of 866.12% is expected in the next year compared to the current price of 1.83. Check the SKYE BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SKYE BIOSCIENCE INC worth?

SKYE BIOSCIENCE INC (SKYE) has a market capitalization of 56.68M USD. This makes SKYE a Micro Cap stock.


How many employees does SKYE BIOSCIENCE INC have?

SKYE BIOSCIENCE INC (SKYE) currently has 11 employees.


What are the support and resistance levels for SKYE BIOSCIENCE INC (SKYE) stock?

SKYE BIOSCIENCE INC (SKYE) has a resistance level at 1.82. Check the full technical report for a detailed analysis of SKYE support and resistance levels.


Should I buy SKYE BIOSCIENCE INC (SKYE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SKYE BIOSCIENCE INC (SKYE) stock pay dividends?

SKYE does not pay a dividend.


When does SKYE BIOSCIENCE INC (SKYE) report earnings?

SKYE BIOSCIENCE INC (SKYE) will report earnings on 2025-05-08, after the market close.


What is the Price/Earnings (PE) ratio of SKYE BIOSCIENCE INC (SKYE)?

SKYE BIOSCIENCE INC (SKYE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).


What is the Short Interest ratio of SKYE BIOSCIENCE INC (SKYE) stock?

The outstanding short interest for SKYE BIOSCIENCE INC (SKYE) is 7.46% of its float. Check the ownership tab for more information on the SKYE short interest.


SKYE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SKYE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SKYE. SKYE has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SKYE Financial Highlights

Over the last trailing twelve months SKYE reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 87.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.51%
ROE -38.98%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%61.9%
Sales Q2Q%N/A
EPS 1Y (TTM)87.22%
Revenue 1Y (TTM)N/A

SKYE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to SKYE. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners85.58%
Ins Owners1.32%
Short Float %7.46%
Short Ratio2.88
Analysts
Analysts84.62
Price Target17.68 (866.12%)
EPS Next Y-70.12%
Revenue Next YearN/A